( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells
ChemMedChem · 2026
DOI: 10.1002/cmdc.70463 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Narges Hosseininasab und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Antineoplastic Agents, Pyrazines, Protein Kinase Inhibitors. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chungbuk National University, National Research Foundation of Korea, Korea government (MSIT).
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) remains a major clinical challenge due to the absence of effective targeted therapies. In this study, thirty analogs of ( S )‐1‐oxo‐1,2,3,4‐tetrahydropyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide ( A1 – F5 ) were designed, synthesized, and evaluated for their cytotoxic activity against hormone receptor‐positive breast cancer (MCF‐7) and EGFR‐overexpressing TNBC (MDA‐MB‐468) cell lines. Notably, compounds B1 and B3 exhibited potent growth inhibition toward MDA‐MB‐468 cells, with GI 50 values of 2.8 and 4.7 µM, respectively, surpassing the efficacy of the reference compound ( Ref 2 , GI 50 : 7.6 µM) and gefitinib (GI 50 : 16.5 µM). Flow cytometric analysis demonstrated significant apoptosis induction by compounds B1 and B3 , with rates of 42.8% and 42.2%, respectively. Mechanistic investigations revealed that compounds B1 and B3 selectively inhibited Akt phosphorylation and enhanced JNK phosphorylation, suggesting a dual modulation of survival and apoptotic pathways. These findings support the development of N2 ‐benzyl‐( S )‐1‐oxo‐1,2,3,4‐tetrahydropyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide analogs, particularly compound B1 , as selective therapeutic candidates for triple‐negative breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
- College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
- Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of Korea.
ORCID-Profile: Soonsil Hyun, Jae-Hwan Kwak
Förderung
- Chungbuk National University
- National Research Foundation of Korea
- Korea government (MSIT)
Zitieren
APA
Hosseininasab, N., Kim, S. H., Kwon, Y. M., Park, J., Jung, C., Lee, K., Wi, B. J., Yoo, S. J., Hyun, S., Jung, Y. S., & Kwak, J. H. (2026). ( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells. ChemMedChem. https://doi.org/10.1002/cmdc.70463
Vancouver
Hosseininasab N, Kim SH, Kwon YM, Park J, Jung C, Lee K, et al. ( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells. ChemMedChem. 2026. doi:10.1002/cmdc.70463
BibTeX
@article{Hosseininasab2026,
author = {Hosseininasab, Narges and Kim, Sou Hyun and Kwon, Ye-Mi and Park, Jungjin and Jung, Chanhyun and Lee, Kwanghee and Wi, Beom-Jun and Yoo, Su-Jin and Hyun, Soonsil and Jung, Young-Suk and Kwak, Jae-Hwan},
title = {( S )‐Pyrrolo[1,2‐ a ]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70463}
}
EUVIMED